Danish multinational pharmaceutical company Novo Nordisk has over 100 years of experience and are globally serving a record of almost 40 million patients.
Way underestimating growth for Wegovy and terminal rate of 2% is also far off which is why the DCF doesnt make sense. This is the reason why both Novo and Eli Lilly has high multiples.
Way underestimating growth for Wegovy and terminal rate of 2% is also far off which is why the DCF doesnt make sense. This is the reason why both Novo and Eli Lilly has high multiples.